Inherited platelet disorders

Journal of Veterinary Emergency and Critical Care

Volumn 22, Issue 1, 2012, Pages 30-41

  Boudreaux, Mary K ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Bleeding disorders; Congenital; Molecular basis; Thrombocytopenia; Thrombopathia

Indexed keywords

ANIMAL; BLOOD CLOTTING DISORDER; GENETIC PREDISPOSITION; GENETICS; HUMAN; REVIEW; THROMBOCYTE DISORDER;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELET DISORDERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

ANIMALIA;

EID: 84864322397     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2011.00702.x     Document Type: Review

References (106)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69(2):454-459.
2. Johnson GS, Turrentine MA, Kraus KH. Canine von Willebrand's disease. A heterogenous group of bleeding disorders. Vet Clin North Am Small Anim Pract 1988; 18(1):195-229.
3. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217-246.
4. Brooks M, Raymond S, Catalfamo J. Severe, recessive von Willebrand's disease in German Wirehaired Pointers. J Am Vet Med Assoc 1996; 209(5):926-929.
5. Kramer JW, Venta PJ, Klein SR, et al. A von Willebrand's factor genomic nucleotide variant and polymerase chain reaction diagnostic test associated with inheritable type-2 von Willebrand's disease in a line of German shorthaired pointer dogs. Vet Pathol 2004; 41(3):221-228.
6. Brooks MB, Dodds JW, Raymond SL. Epidemiologic features of von Willebrand's disease in Doberman Pinschers, Scottish Terriers, and Shetland Sheepdogs: 260 cases (1984-1988). J Am Vet Med Assoc 1992; 200(8):1123-1127.
7. Raymond SL, Jones DW, Brooks MB, Dodds JW. Clinical and laboratory features of a severe form of von Willebrand disease in Shetland Sheepdogs. J Am Vet Med Assoc 1990; 197(10):1342-1346.
8. Johnson GS, Lees GE, Benson RE, et al. A bleeding disease (von Willebrand's disease) in a Chesapeake Bay Retriever. J Am Vet Med Assoc 1980; 176(11):1261-1263.
9. Venta PJ, Li J, Yuzbasivan-Gurkan V, et al. Mutation causing von Willebrand's disease in Scottish Terriers. J Vet Intern Med 2000; 14(1):10-19.
10. Rieger M, Schwarz HP, Turecek PL, et al. Identification of mutations in the canine von Willebrand factor gene associated with type III von Willebrand disease. Thromb Haemost 1998; 80(2):332-337.
11. Slappendel RJ, Beijer EG, van Leeuwen M. Type III von Willebrand's disease in Dutch Kooiker dogs. Vet Q 1998; 20(3):93-97.
12. van Oost BA, Versteeg SA, Slappendel RJ. DNA testing for type III von Willebrand disease in Dutch Kooiker dogs. J Vet Intern Med 2004; 18(3):282-288.
13. Stokol T, Parry BW, Mansell PD. Factor VIII activity in canine von Willebrand disease. Vet Clin Pathol 1995; 24(3):81-90.
14. Benson RE, Catalfamo JL, Brooks M, et al. A sensitive immunoassay for von Willebrand factor. J Immunol 1991; 12(3):371-390.
15. Johnson GS, Turrentine MA, Tomlinson JL. Detection of von Willebrand's disease in dogs with a rapid qualitative test based on venom-coagglutinin-induced platelet agglutination. Vet Clin Pathol 1985; 14(2):11-18.
16. Sabino EP, Erb HN, Catalfamo JL. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs. Am J Vet Res 2006; 67(2):242-249.
17. Stokol T, Trepanier L, Parry BW, et al. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res Vet Sci 1997; 63(1):23-27.
18. Ching YNLH, Meyers KM, Brassard JA, et al. Effect of cryoprecipitate and plasma on plasma von Willebrand factor multimers and bleeding time in Doberman Pinschers with type-I von Willebrand's disease. Am J Vet Res 1994; 55(1):102-110.
19. Warrier AL, Lusher JM. A useful alternative to blood components in moderate hemophilia A and von Willebrand's disease. J Ped 1983; 102:175-200.
20. Rodeghiero F, Castaman G, Tosetto A. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology Am Soc Hematol Educ Program 2009:113-123.
21. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003; 88(6):EREP02
22. Giger U, Dodds JW. Effect of desmopressin in normal dogs and dogs with von Willebrand's disease. Vet Clin Pathol 1989; 18(2):39-42.
23. Callan MB, Giger U, Catalfamo JL. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease. Am J Vet Res 2005; 66(5):861-867.
24. French TW, Fox LE, Randolph JF, et al. A bleeding disorder (von Willebrand's disease) in a Himalayan cat. J Am Vet Med Assoc 1987; 190(4):437-439.
25. Brooks M, Leith GS, Allen AK, et al. Bleeding disorder (von Willebrand disease) in a Quarter horse. J Am Vet Med Assoc 1991; 198(1):114-116.
26. Rathgeber RA, Brooks MB, Bain FT, et al. Clinical vignette. Von Willebrand disease in a Thoroughbred mare and foal. J Vet Intern Med 2001; 15(1):63-66.
27. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82(5):368-375.
28. Tarnow I, Kristensen AT, Texel H, et al. Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2003; 17(5):680-686.
29. Tarnow I, Kristensen AT, Olsen LH, et al. Dogs with heart diseases causing turbulent high-velocity blood flow have changes in platelet function and von Willebrand factor multimer distribution. J Vet Intern Med 2005; 19(4):515-522.
30. Cheville NF. The gray Collie syndrome (cyclic neutropenia). J Am Anim Hosp Assoc 1975; 11:350-352.
31. DiGiacomo RF, Hammond WP, Kunz LL, et al. Clinical and pathologic features of cyclic hematopoiesis in grey collie dogs. Am J Pathol 1983; 111(2):224-233.
32. Lothrop CD, Candler RV, Pratt HL, et al. Characterization of platelet function in cyclic hematopoietic dogs. Exp Hematol 1991; 19(9):916-922.
33. Benson KF, Li FQ, Person RE, et al. Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase. Nat Genet 2003; 35(1):90-96.
34. Kaplan J, DeDomenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15(1):22-29.
35. Kramer JW, Davis WC, Prieur DJ. The Chediak-Higashi syndrome of cats. Lab Invest 1977; 36(5):554-562.
36. Padgett GA, Leader RW, Gorham JR, et al. The familial occurrence of the Chediak-Higashi syndrome in mink and cattle. Genetics 1964; 49(3):505-512.
37. Ridgway SH. Reported causes of death of captive killer whales. J Wildl Dis 1979; 15(1):99-104.
38. Sjaastad OV, Blom AK, Stormorken H, et al. Adenine nucleotides, serotonin, and aggregation properties of platelets of blue foxes (Alopex lagopus) with the Chediak-Higashi syndrome. Am J Med Genet 1990; 35(3):373-378.
39. Ayers JR, Leipold HW, Padgett GA. Lesions in Brangus cattle with Chediak-Higashi syndrome. Vet Pathol 1988; 25(6):432-436.
40. Honda N, Ohnishi K, Fujishiro I, et al. Alteration of release and role of adenosine diphosphate and thromboxane A2 during collagen-induced aggregation of platelets from cattle with Chediak-Higashi syndrome. Am J Vet Res 2007; 88(12):1399-1406.
41. Umemura T, Katsuta O, Goryo M, et al. Pathological findings in a young Japanese Black cattle affected with Chediak-Higashi syndrome. Jpn J Vet Sci 1983; 45(2):241-246.
42. Kunieda T, Nakagiri M, Takami M, et al. Cloning of bovine LYST gene and identification of a missense mutation associated with Chediak-Higashi syndrome of cattle. Mamm Genome 1999; 10(12):1146-1149.
43. Callan MB, Bennett JS, Phillips DK, et al. Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADPdeficiency. Thromb Haemost 1995; 74(3):949-953.
44. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010; 411(1-2):1-6.
45. Boudreaux MK, Kvam K, Dillon AR, et al. Type I Glanzmann's thrombasthenia in a Great Pyrenees dog. Vet Pathol 1996; 33(5):503-511.
46. Boudreaux MK, Lipscomb DL. Clinical, biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs. Vet Pathol 2001; 38(3):249-260.
47. Lipscomb DL, Bourne C, Boudreaux MK. Two genetic defects in αIIb are associated with Type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13. Vet Pathol 2000; 37(6):581-588.
48. Dodds WJ. Familial canine thrombocytopathy. Thromb Diath Haemorrh Suppl 1967; 26:241-248.
49. Boudreaux MK, Catalfamo JL. The molecular basis for Glanzmann's thrombasthenia in Otterhounds. Am J Vet Res 2001; 62(11):1797-1804.
50. Livesey L, Christopherson P, Hammond A, et al. 2005. Platelet dysfunction (Glanzmann's thrombasthenia) in horses. J Vet Intern Med 2005; 19(6):917-919.
51. Christopherson PW, van Santen VL, Livesey L, et al. A 10-base-pair deletion in the gene encoding platelet glycoprotein IIb associated with Glanzmann thrombasthenia in a horse. J Vet Intern Med 2007; 21(1):196-198.
52. Christopherson PW, Insalaco TA, van Santen VL, et al. Characterization of the cDNA encoding αIIb and β3 in normal horses and two horses with Glanzmann thrombasthenia. Vet Pathol 2006; 43(1):78-82.
53. Sanz MG, Wills TB, Christopherson P, et al. Glanzmann thrombasthenia in a 17-year old Peruvian Paso mare. Vet Clin Pathol 2011; 40(1):48-51.
54. Macieira S, Rivard GE, Champagne J, et al. Glanzmann thrombasthenia in an Oldenbourg filly. Vet Clin Pathol 2007; 36(2):204-208.
55. Sutherland RJ, Cambridge H, Bolton JR. Functional and morphological studies on blood platelets in a thrombasthenic horse. Aust Vet J 1989; 66(11):366-370.
56. Miura N, Senba H, Ogawa H, et al. A case of equine thrombasthenia. Jpn J Vet Sci 1987; 49(1):155-158.
57. Fang J, Jensen E, Boudreaux M, et al. Platelet gene therapy; improved hemostatic function for integrin αIIbβ3 deficient dogs. Proc Natl Acad Sci USA 2011; 108(23):9583-9588.
58. Oury C, Toth-Zsamboki E, Vermylen J, et al. The platelet ATP andADP receptors. Curr Pharm Des 2006; 12(7):859-875.
59. Watson S, Daly M, Dawood B, et al. Phenotypic approaches to gene mapping in platelet function disorders. Identification of new variant P2Y12, TXA2, and GPVI receptors. Hämostaseologie 2010; 30(1):29-38.
60. Shiraga M, Miyata S, Kato H, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005; 3(10):2315-2323.
61. Boudreaux MK, Martin M. P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. Vet Clin Pathol 2011; 40(2):202-206.
62. Boudreaux MK, Panangala VS, Bourne C. A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen. Vet Pathol 1996; 33(4):419-427.
63. Ivanov AA, Costanzi S, Jacobson KA. Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. J Comput Aided Mol Des 2006; 20(7-8):417-426.
64. Callan MB, Walton R, Jezyk PF, et al. Thrombopathies causing bleeding in a boxer and mixed-breed dog. J Am Anim Hosp Assoc 2001; 37(3):244-250.
65. Rao AK, Gabbeta J. Congenital disorders of platelet signal transduction. Arterioscler Thromb Vasc Biol 2000; 20(2):285-289.
66. Bernardi B, Guidetti GF, Campus F, et al. The small GTPase Rap1b regulates the cross talk between platelet integrin α2 β1 and integrin αIIbβ3. Blood 2006; 107(7):2728-2735.
67. Bergmeier W, Stefanini L. Novel molecules in calcium signaling in platelets. J Thromb Haemost 2009; 7(Suppl 1):187-190.
68. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39(18):5458-5467.
69. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10(9):982-986.
70. Johnstone IB, Lotz F. An inherited platelet function defect in basset hounds. Can Vet J 1979; 20(8):211-215.
71. Catalfamo JL, Raymond SL, White JG, et al. Defective platelet-fibrinogen interaction in hereditary canine thrombopathia. Blood 1986; 67(6):1568-1577.
72. Boudreaux MK, Catalfamo JL, Klok M. Calcium diacylglycerol guanine nucleotide exchange factor I gene mutations associated with loss of function in canine platelets. Transl Res 2007; 150(2):81-92.
73. Boudreaux MK, Crager C, Dillon AR, et al. Identification of an intrinsic platelet function defect in Spitz dogs. J Vet Intern Med 1994; 8(2):93-98.
74. Steficek BA, Thomas JS, McConnell MF, et al. A primary platelet disorder of consanguineous Simmental cattle. Thromb Res 1993; 72(2):145-153.
75. Gentry PA, Cheryk LA, Shanks RD, et al. An inherited platelet function defect in a Simmental crossbred herd. Can J Vet Res 1997; 61(2):128-133.
76. Frojmovic MM, Wong T, Searcy GP. Platelets from bleeding Simmental cattle have a long delay in both ADP-activated expression of GPIIb-IIIa receptors and fibrinogen-dependent platelet aggregation. Thromb Haemost 1996; 76(6):1047-1052.
77. Searcy GP, Frojmovic MM, McNicol A, et al. Platelets from bleeding Simmental cattle mobilize calcium, phosphorylate myosin light chain and bind normal numbers of fibrinogen molecules but have abnormal cytoskeletal assembly and aggregation in response to ADP. Thromb Haemost 1994; 71(2):240-246.
78. Boudreaux MK, Schmutz S, French PS. Calcium diacylglycerol guanine nucleotide exchange factor I (CalDAG-GEFI) gene mutations in a thrombopathic Simmental calf. Vet Pathol 2007; 44(6):932-935.
79. Pasvolsky R, Feigelson SW, Kilic SS, et al. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets. J Exp Med 2007; 204(7):1571-1582.
80. Kilic SS, Etzioni A. The clinical spectrum of leukocyte adhesion deficiency (LAD) III due to defective CalDAG-GEFI. J Clin Immunol 2009; 29(1):117-122.
81. Kuijpers TW, van de Vijver E, Weterman MAJ, et al. LAD1/variant syndrome is caused by mutations in FERMT3. Blood 2009; 113(19):4740-4746.
82. Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3affecting integrin activation. Nat Med 2009; 15(3):306-312.
83. Malinin NL, Zhang L, Choi J, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009; 15(3):313-318.
84. Etzioni A. Defects in the leukocyte adhesion cascade. Clin Rev Allergy Immunol 2010; 38(1):54-60.
85. Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2009; 14(3):325-330.
86. Boudreaux MK, Wardrop KJ, Kiklevich V, et al. A mutation in the canine kindlin-3 gene associated with increased bleeding risk and susceptibility to infections. Thromb Haemost 2010; 103(2):475-477.
87. Zwall RFA, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636:119-128.
88. Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002; 99(7):2434-2441.
89. Brooks MB, Catalfamo JL, Friese P, et al. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. J Thromb Haemost 2007; 5(9):1972-1974.
90. Brooks MB, Randolph J, Warner K, et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009; 38(3):306-315.
91. Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87(4):1409-1415.
92. Brooks M, Etter K, Catalfamo J, et al. A genome-wide linkage scan in German shepherd dogs localizes canine platelet procoagulant deficiency (Scott syndrome) to canine chromosome 27. Gene 2010; 450(2):70-75.
93. Eksell P, Haggstrom J, Kvart D, et al. Thrombocytopenia in the Cavalier King Charles spaniel. J Small Anim Prac 1994; 35(3):153-155.
94. Cowan SM, Bartges JW, Gompf RE, et al. Giant platelet disorder in the Cavalier King Charles Spaniel. Exp Hematol 2004; 32(4):344-350.
95. Singh MK, Lamb WA. Idiopathic thrombocytopenia in Cavalier King Charles Spaniels. Aust Vet J 2005; 83(11):700-703.
96. Smedile LE, Houston DM, Taylor SM, et al. Idiopathic, asymptomatic thrombocytopenia in Cavalier King Charles Spaniels: 11 cases (1983-1993). J Am Anim Hosp Assoc 1997; 33(5):411-415.
97. Pedersen HD, Haggstrom J, Olsen LH, et al. Idiopathic asymptomatic thrombocytopenia in Cavalier King Charles Spaniels is an autosomal recessive trait. J Vet Intern Med 2002; 16(2):169-173.
98. Davis B, Toivio-Kinnucan M, Schuller S, et al. Mutation in β1-tubulin correlates with the macrothrombocytopenia of Cavalier King Charles Spaniels. J Vet Intern Med 2008; 22(3):540-545.
99. Kunishima S, Kobayashi R, Itoh TJ, et al. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009; 113(2):458-461.
100. Pedersen HD, Lorentzen KA, Kristensen BO. Echocardiographic mitral valve prolapse in cavalier King Charles spaniels: epidemiology and prognostic significance for regurgitation. Vet Rec 1999; 144(12):315-320.
101. Narishige T, Blade KL, Ishibashi Y, et al. Cardiac hypertrophy and developmental regulation of the beta-tubulin multigene family. J Biol Chem 1999; 274(14):9692-9697.
102. Koide M, Hamawaki M, Narishige T, et al. Microtubule depolymerization normalizes in vivo myocardial contractile function in dogs with pressure-overload left ventricular hypertrophy. Circulation 2000; 102(9):1045-1052.
103. Saji K, Fukumoto Y, Suzuki J, et al. Colchicine, a microtubule depolymerizing agent, inhibits myocardial apoptosis in rats. Tohoku J Exp Med 2007; 213(2):139-148.
104. Gelain ME, Tutino GF, Pogliani E, et al. Macrothrombocytopenia in a group of related Norfolk terriers. Vet Rec 2010; 167(13):493-494.
105. Althaus K, Greinacher A. MYH-9 related platelet disorders: strategies for management and diagnosis. Transfus Med Hemother 2010; 37(5):260-267.
106. Flatland B, Fry MM, Baek SJ, et al. May-Hegglin anomaly in a dog. Vet Clin Pathol 2011; 40(2):207-214.